中国医学创新2025，Vol.22Issue(32)：1-4,4.DOI:10.3969/j.issn.1674-4985.2025.32.001
以硼替佐米为基础的化疗在多发性骨髓瘤患者中的应用效果
Application Effect of Bortezomib-based Chemotherapy in Patients with Multiple Myeloma
摘要
Abstract
Objective:To investigate the application effect of Bortezomib-based chemotherapy in patients with multiple myeloma.Method:A total of 60 multiple myeloma patients admitted to the Department of Hematology,Yichun People's Hospital from February 2020 to February 2022 were selected as the study subjects.They were divided into two groups according to the random number table method.The control group(n=30)was treated with the Rd regimen,and the observation group(n=30)was treated with the RVD regimen.The immune-related cytokines,basic T cell subsets,functional T cell subsets and curative effects were compared between the two groups.Result:After 4 courses of treatment,the levels of helper T cell 17(Th17)in both groups decreased,the levels of CD4+/CD8+and regulatory T cells(Treg)increased,and those in the observation group were superior to the control group(P<0.05).Compared with the control group,the levels of transforming growth factor-β1(TGF-β1),IL-17 and IL-6 in the observation group after 4 courses of treatment were lower(P<0.05).After 4 courses of treatment,the total effective rate of treatment in the observation group was higher than that in the control group(P<0.05).Conclusion:For patients with multiple myeloma,chemotherapy regimen based on Bortezomib can regulate T cell subsets,improve immune-related cytokines,and enhance curative effect.关键词
多发性骨髓瘤/硼替佐米/T细胞亚群Key words
Multiple myeloma/Bortezomib/T cell subsets引用本文复制引用
杨新平,卢玉华,曾文兴,谢春,李明..以硼替佐米为基础的化疗在多发性骨髓瘤患者中的应用效果[J].中国医学创新,2025,22(32):1-4,4.基金项目
江西省卫生健康委科技计划项目(skjp220203301) （skjp220203301）
